UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation

Bone marrow transplantation (Basingstoke), 2016-12, Vol.51 (12), p.1588-1593

2016

Volltextzugriff (PDF)

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

Leukemia, 2012-05, Vol.26 (5), p.893-901

2012

Volltextzugriff (PDF)

Isocitrate dehydrogenase mutations in myeloid malignancies

Leukemia, 2017-02, Vol.31 (2), p.272-281

2017

Volltextzugriff (PDF)

Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index

Bone marrow transplantation (Basingstoke), 2013-09, Vol.48 (9), p.1253-1256

2013

Volltextzugriff (PDF)

Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation

Bone marrow transplantation (Basingstoke), 2007-12, Vol.40 (11), p.1027-1032

2007

Volltextzugriff (PDF)

Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning

Bone marrow transplantation (Basingstoke), 2006-02, Vol.37 (3), p.307-310

2006

Volltextzugriff (PDF)

P570: REAL‐WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

HemaSphere, 2022-06, Vol.6, p.469-470

2022

Volltextzugriff (PDF)

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER‐RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS

HemaSphere, 2022-06, Vol.6, p.67-68

2022

Volltextzugriff (PDF)

P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX‐BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE

HemaSphere, 2022-06, Vol.6, p.418-419

2022

Volltextzugriff (PDF)

TNP-470 promotes initial vascular sprouting in xenograft tumors

Molecular cancer therapeutics, 2004-03, Vol.3 (3), p.335-343

2004

Volltextzugriff (PDF)

The Role of Chemistry in Fracture Pattern Development and Opportunities to Advance Interpretations of Geological Materials

Reviews of geophysics (1985), 2019-09, Vol.57 (3), p.1065-1111

2019

Volltextzugriff (PDF)

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

The lancet oncology, 2018-02, Vol.19 (2), p.216-228

2018

Volltextzugriff (PDF)

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Cancer discovery, 2016-10, Vol.6 (10), p.1106-1117

2016

Volltextzugriff (PDF)

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

American journal of hematology, 2021-02, Vol.96 (2), p.208-217

2021

Volltextzugriff (PDF)

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Leukemia, 2019-11, Vol.33 (11), p.2575-2584

2019

Volltextzugriff (PDF)

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

Blood advances, 2019-10, Vol.3 (20), p.2911-2919

2019

Volltextzugriff (PDF)

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Blood cancer journal (New York), 2020-10, Vol.10 (10), p.107-107, Article 107

2020

Volltextzugriff (PDF)

Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?

American journal of hematology, 2024-09, Vol.99 (9), p.1790-1801

2024

Volltextzugriff (PDF)

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

Blood advances, 2022-07, Vol.6 (13), p.3879-3883

2022

Volltextzugriff (PDF)

Directional semivariogram analysis to identify and rank controls on the spatial variability of fracture networks

Journal of structural geology, 2018-03, Vol.108, p.34-51

2018

Volltextzugriff (PDF)

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial

The Lancet. Haematology, 2020-04, Vol.7 (4), p.e309-e319

2020

Volltextzugriff (PDF)

Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study

American journal of hematology, 2023-09, Vol.98 (9), p.E233-E236

2023

Volltextzugriff (PDF)

Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response

Clinical lymphoma, myeloma and leukemia, 2020-02, Vol.20 (2), p.e66-e75

2020

Volltextzugriff (PDF)

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC‐LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML‐M4 AND AML‐M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)

HemaSphere, 2023-08, Vol.7 (S3), p.e160928c-n/a

2023

Volltextzugriff (PDF)

1 – 25 von 53

Suche als RSS-Feed

Aktive Filter

KollektionPublisher website

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(49)

Publikationsform

Artikel
(51)
Buchkapitel
(2)

Sprache

Englisch
(53)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

Isocitrate dehydrogenase mutations in myeloid malignancies

Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index

Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation

Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioning

P570: REAL‐WORLD EFFICACY OUTCOMES OF VENETOCLAX PLUS AZACITIDINE VS INTENSIVE CHEMOTHERAPY FOR INDUCTION THERAPY IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER‐RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS

P519: TRANSFUSION INDEPENDENCE AMONG NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS RECEIVING VENETOCLAX‐BASED COMBINATIONS VS OTHER THERAPIES: RESULTS FROM THE AML REAL WORLD EVIDENCE (ARC) INITIATIVE

Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study

TNP-470 promotes initial vascular sprouting in xenograft tumors

The Role of Chemistry in Fracture Pattern Development and Opportunities to Advance Interpretations of Geological Materials

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia

New directions for emerging therapies in acute myeloid leukemia: the next chapter

Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?

Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia

Directional semivariogram analysis to identify and rank controls on the spatial variability of fracture networks

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial

Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study

Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC‐LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML‐M4 AND AML‐M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)

Aktive Filter

Suchergebnisse filtern